mylan hope bulk fend unwant takeov advanc dash tuesday night ireland perrigo reject 30bn 20bn takeov bid rebutt perrigo came hour mylan fell prey separ 40bn hostil approach rival generic drug maker teva telavivbas teva said would offer mylan investor 82 share split equal cash share bid gatecrash mylan propos perrigo deal howev perrigo said unanim reject newyorklist compani offer substanti undervalu compani growth prospect industri sourc frequent specul tieup teva mylan latter move perrigo spur isra group action perrigo move ireland tax reason invers takeov dublinbas elan mylan incorpor netherland follow takeov abbott generic arm last august howev mylan base potter bar hertfordshir despit still oper main busi pittsburgh us keep new york list compani claim make one everi 11 drug prescrib american teva hostil bid fresh evid frenzi pace deal make pharmaceut sector approach push number announc deal sector 1476bn alreadi year 247pc time last year best start year sinc 1980 accord thomson reuter teva approach come mylan took unusu unpreced step dismiss potenti deal last week isra rival gone public bid mylan chairman robert couri said compani previous studi combin teva said combin without sound industri logic cultur fit also rais concern tieup isra rival would prompt competit concern howev teva chief execut erez vigodman public rebuk opposit number mylan said letter disappoint prematur address potenti combin press releas teva said deal would creat generic powerhous revenu 30bn provid mylan stockhold attract altern mylan propos acquisit perrigo well mylan standalon basi isra group also said offer 377pc premium mylan share price announc offer perrigo mylan busi natur fit high complementari bring togeth two compani would deliv greatest valu financi stakehold also enabl us better serv patient custom healthcar system throughout world mr vigodman said 